Product References
Down-syndrome-induced senescence disrupts the nuclear architecture of neural progenitors.
Cell stem cell
Meharena HS,Marco A,Dileep V,Lockshin ER,Akatsu GY,Mullahoo J,Watson LA,Ko T,Guerin LN,Abdurrob F,Rengarajan S,Papanastasiou M,Jaffe JD,Tsai LH
PA1-16926 was used in Immunocytochemistry to provide a mechanistic link between T21 and global transcriptional disruption and indicate that senescence-associated phenotypes may play a key role in the neurodevelopmental pathogenesis of DS.
Thu Jan 06 00:00:00 UTC 2022
Pentoxifylline prevents epileptic seizure via modulating HMGB1/RAGE/TLR4 signalling pathway and improves memory in pentylenetetrazol kindling rats.
Clinical and experimental pharmacology & physiology
Badawi GA,Shokr MM,Zaki HF,Mohamed AF
PA1-16926 was used in ChIP Assay, ELISA, Flow Cytometry, Immunocytochemistry, Immunohistochemistry (Paraffin), Western Blot to find that PTX or its combination with phenytoin represent a promising drug to inhibit the epilepsy progression via targeting the HMGB1/TLR4/RAGE signalling pathway.
Sun Aug 01 00:00:00 UTC 2021
Pentoxifylline prevents epileptic seizure via modulating HMGB1/RAGE/TLR4 signalling pathway and improves memory in pentylenetetrazol kindling rats.
Clinical and experimental pharmacology & physiology
Badawi GA,Shokr MM,Zaki HF,Mohamed AF
PA1-16926 was used in ChIP Assay, ELISA, Flow Cytometry, Immunocytochemistry, Immunohistochemistry (Paraffin), Western Blot to find that PTX or its combination with phenytoin represent a promising drug to inhibit the epilepsy progression via targeting the HMGB1/TLR4/RAGE signalling pathway.
Sun Aug 01 00:00:00 UTC 2021
The Potential of Nanobody-Targeted Photodynamic Therapy to Trigger Immune Responses.
Cancers
Beltrán Hernández I,Angelier ML,Del Buono D'Ondes T,Di Maggio A,Yu Y,Oliveira S
Published figure using HMGB1 polyclonal antibody (Product # PA1-16926) in Immunocytochemistry
Wed Apr 15 00:00:00 UTC 2020
The Potential of Nanobody-Targeted Photodynamic Therapy to Trigger Immune Responses.
Cancers
Beltrán Hernández I,Angelier ML,Del Buono D'Ondes T,Di Maggio A,Yu Y,Oliveira S
Published figure using HMGB1 polyclonal antibody (Product # PA1-16926) in Immunocytochemistry
Wed Apr 15 00:00:00 UTC 2020
A small bioactive glycoside inhibits epsilon toxin and prevents cell death.
Disease models & mechanisms
Shivappagowdar A,Pati S,Narayana C,Ayana R,Kaushik H,Sah R,Garg S,Khanna A,Kumari J,Garg L,Sagar R,Singh S
Published figure using HMGB1 polyclonal antibody (Product # PA1-16926) in Immunocytochemistry
Thu Oct 10 00:00:00 UTC 2019
A small bioactive glycoside inhibits epsilon toxin and prevents cell death.
Disease models & mechanisms
Shivappagowdar A,Pati S,Narayana C,Ayana R,Kaushik H,Sah R,Garg S,Khanna A,Kumari J,Garg L,Sagar R,Singh S
Published figure using HMGB1 polyclonal antibody (Product # PA1-16926) in Immunocytochemistry
Thu Oct 10 00:00:00 UTC 2019
Expression Analysis of Autophagy Related Markers LC3B, p62 and HMGB1 Indicate an Autophagy-Independent Negative Prognostic Impact of High p62 Expression in Pulmonary Squamous Cell Carcinomas.
Cancers
Langer R,Neppl C,Keller MD,Schmid RA,Tschan MP,Berezowska S
Published figure using HMGB1 polyclonal antibody (Product # PA1-16926) in Immunohistochemistry
Tue Aug 21 00:00:00 UTC 2018
The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer.
Autophagy
Ladoire S,Enot D,Senovilla L,Ghiringhelli F,Poirier-Colame V,Chaba K,Semeraro M,Chaix M,Penault-Llorca F,Arnould L,Poillot ML,Arveux P,Delaloge S,Andre F,Zitvogel L,Kroemer G
Published figure using HMGB1 polyclonal antibody (Product # PA1-16926) in Immunohistochemistry
Tue May 03 00:00:00 UTC 2016
The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer.
Autophagy
Ladoire S,Enot D,Senovilla L,Ghiringhelli F,Poirier-Colame V,Chaba K,Semeraro M,Chaix M,Penault-Llorca F,Arnould L,Poillot ML,Arveux P,Delaloge S,Andre F,Zitvogel L,Kroemer G
Published figure using HMGB1 polyclonal antibody (Product # PA1-16926) in Immunohistochemistry
Tue May 03 00:00:00 UTC 2016
Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate.
Oncoimmunology
Ladoire S,Senovilla L,Enot D,Ghiringhelli F,Poirier-Colame V,Chaba K,Erdag G,Schaefer JT,Deacon DH,Zitvogel L,Slingluff CL,Kroemer G
PA116926 was used in immunohistochemistry - paraffin section to analyze immunogenic biomarkers and immune cells infiltrarion and prognosis in metastasis.
Wed Jun 01 00:00:00 UTC 2016
Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.
Autophagy
Ladoire S,Penault-Llorca F,Senovilla L,Dalban C,Enot D,Locher C,Prada N,Poirier-Colame V,Chaba K,Arnould L,Ghiringhelli F,Fumoleau P,Spielmann M,Delaloge S,Poillot ML,Arveux P,Goubar A,Andre F,Zitvogel L,Kroemer G
PA1-16926 was used in immunohistochemistry - paraffin section to predict residual risk of relapse after adjuvant chemotherapy in breast cancer by combined evaluation of HMGB1 and LC3B puncta
Tue Sep 13 00:00:00 UTC 2016
Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.
Autophagy
Ladoire S,Penault-Llorca F,Senovilla L,Dalban C,Enot D,Locher C,Prada N,Poirier-Colame V,Chaba K,Arnould L,Ghiringhelli F,Fumoleau P,Spielmann M,Delaloge S,Poillot ML,Arveux P,Goubar A,Andre F,Zitvogel L,Kroemer G
PA1-16926 was used in immunohistochemistry - paraffin section to predict residual risk of relapse after adjuvant chemotherapy in breast cancer by combined evaluation of HMGB1 and LC3B puncta
Tue Sep 13 00:00:00 UTC 2016
Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy.
Oncotarget
Vacchelli E,Semeraro M,Enot DP,Chaba K,Poirier Colame V,Dartigues P,Perier A,Villa I,Rusakiewicz S,Gronnier C,Goéré D,Mariette C,Zitvogel L,Kroemer G
PA1-16926 was used in immunohistochemistry - paraffin section to examine the immune responses in patients with esophageal carcinomas treated by neo-adjuvant radiochemotherapy
Fri Aug 28 00:00:00 UTC 2015